目的探讨乳腺癌组织T细胞分化蛋白2(mal T-cell differentiation protein 2,MAL2)、胰岛素样生长因子1受体(insulin like growth factor 1 receptor,IGF-1R)蛋白表达与病理特征及预后的相关性。方法选取营口市中心医院2015年3月~2016年...目的探讨乳腺癌组织T细胞分化蛋白2(mal T-cell differentiation protein 2,MAL2)、胰岛素样生长因子1受体(insulin like growth factor 1 receptor,IGF-1R)蛋白表达与病理特征及预后的相关性。方法选取营口市中心医院2015年3月~2016年3月收治的131例乳腺癌患者,采用免疫组织化学法检测乳腺癌患者癌旁正常组织和癌组织MAL2和IGF-1R蛋白表达水平,分析MAL2和IGF-1R蛋白水平与不同病理特点及预后的关系,并采用COX比例风险回归模型分析乳腺癌患者预后影响因素。结果乳腺癌患者癌组织MAL2(77.86%),IGF-1R蛋白(80.15%)阳性率显著高于癌旁正常组织(17.56%,21.37%),差异有统计学意义(χ^(2)=95.482,90.540,均P<0.05);在不同乳腺癌TMN分期以及分化程度上MAL2和IGF-1R蛋白阳性表达率差异均有统计学意义(χ^(2)_(MAL2)=33.545,16.188,χ^(2)_(IGF-1R)=6.533,12.422,均P<0.001)。131例乳腺癌患者随访期间,预后较差患者59例,预后良好患者72例;预后较差组患者MAL2(94.92%),IGF-1R(91.53%)蛋白阳性表达率显著高于预后良好组(36.11%,41.67%),差异均有统计学意义(χ^(2)=18.110,8.727,均P<0.05)。中低分化、III~IV期、MAL2蛋白阳性表达和IGF-1R蛋白阳性表达是患者不良预后的危险因素(P<0.05)。结论MAL2和IGF-1R蛋白在乳腺癌组织中具有较高的表达水平,且与乳腺癌患者TMN分期和分化程度具有明显的相关性,可能是患者不良预后的危险因素之一。展开更多
Objective: The purpose of the study was to investigate the relationship between the expression of estrogen receptor(ER), progestogen receptor(PR), human epidermal growth factor receptor(Her-2), Ki-67 and the effect of...Objective: The purpose of the study was to investigate the relationship between the expression of estrogen receptor(ER), progestogen receptor(PR), human epidermal growth factor receptor(Her-2), Ki-67 and the effect of neoadjuvant chemotherapy in breast cancer. Methods: The expression of ER, PR, Her-2 and Ki-67 in 45 breast cancers which received neoadjuvant chemotherapy was detected by immunohistochemistry. Results: The effective rates in ER negative and PR negative groups were higher than those in ER positive and PR positive groups(83.3% vs 59. 4%, 82.4% vs 60.6%). There was no significant difference of the effective rate between Her-2 overexpressed group and Her-2 non-overexpressed group(81.8% vs 64.1%), and the same thing happened between Ki-67 negative group and Ki-67 positive group(67.7% vs 63.2%). Conclusion: In the patients with breast cancer, ER, PR negative ones were more sensitive to neoadjuvant chemotherapy. These patients may get more benefits from chemotherapy. ER, PR could be feasible markers for predicting the effective rate of neoadjuvant chemotherapy.展开更多
文摘目的探讨乳腺癌组织T细胞分化蛋白2(mal T-cell differentiation protein 2,MAL2)、胰岛素样生长因子1受体(insulin like growth factor 1 receptor,IGF-1R)蛋白表达与病理特征及预后的相关性。方法选取营口市中心医院2015年3月~2016年3月收治的131例乳腺癌患者,采用免疫组织化学法检测乳腺癌患者癌旁正常组织和癌组织MAL2和IGF-1R蛋白表达水平,分析MAL2和IGF-1R蛋白水平与不同病理特点及预后的关系,并采用COX比例风险回归模型分析乳腺癌患者预后影响因素。结果乳腺癌患者癌组织MAL2(77.86%),IGF-1R蛋白(80.15%)阳性率显著高于癌旁正常组织(17.56%,21.37%),差异有统计学意义(χ^(2)=95.482,90.540,均P<0.05);在不同乳腺癌TMN分期以及分化程度上MAL2和IGF-1R蛋白阳性表达率差异均有统计学意义(χ^(2)_(MAL2)=33.545,16.188,χ^(2)_(IGF-1R)=6.533,12.422,均P<0.001)。131例乳腺癌患者随访期间,预后较差患者59例,预后良好患者72例;预后较差组患者MAL2(94.92%),IGF-1R(91.53%)蛋白阳性表达率显著高于预后良好组(36.11%,41.67%),差异均有统计学意义(χ^(2)=18.110,8.727,均P<0.05)。中低分化、III~IV期、MAL2蛋白阳性表达和IGF-1R蛋白阳性表达是患者不良预后的危险因素(P<0.05)。结论MAL2和IGF-1R蛋白在乳腺癌组织中具有较高的表达水平,且与乳腺癌患者TMN分期和分化程度具有明显的相关性,可能是患者不良预后的危险因素之一。
文摘Objective: The purpose of the study was to investigate the relationship between the expression of estrogen receptor(ER), progestogen receptor(PR), human epidermal growth factor receptor(Her-2), Ki-67 and the effect of neoadjuvant chemotherapy in breast cancer. Methods: The expression of ER, PR, Her-2 and Ki-67 in 45 breast cancers which received neoadjuvant chemotherapy was detected by immunohistochemistry. Results: The effective rates in ER negative and PR negative groups were higher than those in ER positive and PR positive groups(83.3% vs 59. 4%, 82.4% vs 60.6%). There was no significant difference of the effective rate between Her-2 overexpressed group and Her-2 non-overexpressed group(81.8% vs 64.1%), and the same thing happened between Ki-67 negative group and Ki-67 positive group(67.7% vs 63.2%). Conclusion: In the patients with breast cancer, ER, PR negative ones were more sensitive to neoadjuvant chemotherapy. These patients may get more benefits from chemotherapy. ER, PR could be feasible markers for predicting the effective rate of neoadjuvant chemotherapy.
